BARI 2D

BARI 2D

Bypass Angioplasty Revascularization Investigation 2D. A multicentre, multinational trial comparing the mortality of type-2 diabetics with stable coronary artery disease, managing myocardial ischemia either by immediate revascularisation plus intense medical therapy or by intense medical therapy alone, and management of the diabetes by an insulin-sensitising or by an insulin-providing strategy.

Conclusion
There were similar rates of mortality and major cardiovascular events for prompt revascularisation vs delayed or no revascularisation, and insulin sensitisation vs insulin provision. In high-risk patients selected for CABG, prompt revascularisation reduces major cardiovascular events compared with delayed or no revascularisation, a finding that doesn’t hold for low-risk patients selected for percutaneous coronary intervention.
References in periodicals archive ?
To address the cardiovascular disease, patients in BARI 2D were randomly assigned to receive intensive medical therapy plus revascularization treatment (such as angioplasty or bypass surgery) or intensive medical therapy alone (with the possibility of revascularization treatment later if their symptoms did not improve).
Diyabetik CDH'da koroner baypas ve ISS etkinligini karsilastiran randomize kontrollu diger iki buyuk calisma FREEDOM ve BARI 2D (18, 19) calismalari da halen devam etmektedir.
Simdilik genel anestezi sikintisi olan ve buyuk cerrahi girisimi istemeyen ya da ilave hastaliklari nedeni ile yuksek mortalite riski olan CDH'da ISS kesinlikle ciddi bir alternatif imkani sunmaktadir, ilac salinimli stentlerin CDH'da diyabetiklerde, ana koroner arter hastalarinda guvenlik ve etkinligini net bir sekilde degerlendirmek icin FREEDOM, SYNTAX, CARDIA, BARI 2D (16-19) gibi randomize calismalarin "uzun donem sonuclarini" beklemek gerekmektedir.
The data come from the NIH's Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes study, called BARI 2D, which tracked the health of more than 2,000 patients for five years.
That trial, published in NEJM in March 2007, concluded, as did the BARI 2D study, that for patients with mild-to-moderate heart disease symptoms, angioplasty and drug treatment are equally effective at preventing subsequent heart attacks and death.
ORLANDO - Virtually no patients with type 2 diabetes and documented coronary artery disease and coronary ischemia benefit from immediate coronary revascularization, as long as they receive intensive medical management, based on the outcomes of more than 1,000 patients randomized to the deferred revascularization arm of the BARI 2D trial.
The study, known as BARI 2D, (Bypass Angioplasty Revascularization Investigation 2 Diabetes) was also presented yesterday in New Orleans at the American Diabetes Association 69th Scientific Sessions -- a national medical conference.
The BARI 2D study began recruiting patients in 2001.
One of the two primary objectives for the BARI 2D study was to determine if a strategy of initial elective coronary revascularization by either bypass surgery or angioplasty combined with aggressive medical therapy results in a lower five-year mortality compared with a strategy of initial aggressive medical therapy alone.
The BARI 2D findings reinforce the clinical value of SPECT MPI in determining the extent and severity of myocardial ischemia in patients with type 2 diabetes and stable CAD.
A multi-million dollar initiative, BARI 2D is being conducted through more than 35 leading medical research centers across the United States and Canada and is seeking 2,800 participants with type 2 diabetes to determine the best ways to treat patients who have diabetes and early coronary artery disease.
BARI 2D Study Findings to Be Presented at American Diabetes Association Scientific Sessions